STAT:Neurocrine罕见病药物Vykat XR安全性担忧上升
STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug
Neurocrine Biosciences的Vykat XR获批用于Prader-Willi综合征治疗18个月以来,已有七例死亡与近100例住院报告。STAT通过信息公开法案获得提交的病例报告,显示尚无法确立因果关系,但部分专家与患者倡导者认为风险已不可接受。
文章转述患者倡导者与专家对Vykat XR安全性的担忧及监管材料现状,适合了解该药当前争议背景。
Two months after the release of an open letter on potential safety issues tied to a rare disease drug sold by Neurocrine Biosciences, patient advocates and some experts are expressing growing alarm over the perceived risks of the therapy.
The drug, approved to treat Prader-Willi syndrome, which can cause an insatiable feeling of hunger, has been linked to the deaths of seven people and the hospitalization of nearly 100 others — all since the treatment, called Vykat XR, was approved 18 months ago.
Case reports on those deaths and hospitalizations that were submitted to regulators, and that were obtained by STAT through the Freedom of Information Act, do not prove causality; many of the Vykat cases involved complex medical issues and multiple medications. But some experts say the evidence is sufficient to conclude Vykat is causing unacceptable harm.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com